Postmarket surveillance under FDAMA should be last resort to other controls -- HIMA.
This article was originally published in The Gray Sheet
POSTMARKET SURVEILLANCE SHOULD BE LAST RESORT IN FDA's "EARLY WARNING" SYSTEM, the Health Industry Manufacturers Association maintained at a Jan. 15 FDA/industry public meeting in Gaithersburg, Maryland on how to implement revisions to the agency's tracking and postmarket surveillance (PMS) programs mandated by the FDA Modernization Act (FDAMA).
You may also be interested in...
Medical device manufacturers would be able to satisfy postmarket surveillance orders using secondary data collection methods or literature reviews, provided their proposed method answered the surveillance question posed by FDA, under an Aug. 29 proposed rule.
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.